The purpose of the project is to improve outcomes of liver transplantation among African Americans by conducting clinical and biochemical investigations. The project includes several components whose findings will be studied individually and in conjunction with each other to determine optimally effective therapies an protocols. Clinical investigations will involve immunosuppression, infection control, and non-heart-beating donors.
The specific aims of the clinical components are to answer: (1) How can immunosuppression in African American transplant patients be optimized without increases in infection rates? (2) Can infection after transplantation be controlled in African American liver recipients? and (3) Are livers from non-heart-beating donors suitable for transplantation? Clinical investigations of immunosuppression will involve assessment of the effects of cyclosporine, OKT3, and FK506. Infection control will focus on cytomegalovirus. The clinical investigations also will explore the potential of non-heart-beating donors in increasing the supply of livers for transplantation. Biochemical investigations will focus on genetics, pharmacokinetics, and measures of liver function.
The specific aims of the biochemical investigation are to answer: (1) Can genetics tests predict the amount of FK-506 and cyclosporine that should be administered to African American liver recipients? (2) How can the immunosuppressive properties of FK-506 and cyclosporine be optimized? and (3) Can assessment of liver status be improved to facilitate clinical decision making? One portion of the biochemical studies will gather data on dosage of FK-506 and cyclosporine in conjunction with other drugs by examining the role of genetics in the activity of cytochrome P450 IIIA4. The pharmacokinetics of FK-506 and cyclosporine will be investigated by determining how metabolites and diet influence the drugs immunosuppressive properties. Assessment of in vivo liver status will be conducted by measuring cytochrome oxidase activity and hepatic blood flow.

Project Start
1997-04-01
Project End
1999-09-29
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Howard University
Department
Type
DUNS #
056282296
City
Washington
State
DC
Country
United States
Zip Code
20059
Popa, Laurentiu S; Hewitt, Angela L; Ebner, Timothy J (2013) Purkinje cell simple spike discharge encodes error signals consistent with a forward internal model. Cerebellum 12:331-3
Fuller, T L; Canada, R G (1999) Enhancement of cisplatin cytotoxicity by terbium in cisplatin-resistant MDA/CH human breast cancer cells. Cancer Chemother Pharmacol 44:249-52
Canada, R G; Paltoo, D N (1998) Binding of terbium and cisplatin to C13* human ovarian cancer cells using time-resolved terbium luminescence. Biochim Biophys Acta 1448:85-98
Paltoo, D N; Canada, R G (1998) Effects of terbium on the cytotoxicity of cisplatin in FaDu human head and neck squamous cell carcinoma. Cancer Biochem Biophys 16:213-27
Ting, P; Cushenberry, P A; Friedman, T C et al. (1997) Enhanced brain opioid receptor activity precedes blood-brain barrier disruption. Acta Neurochir Suppl 70:250-3
Mack, K M; Canada, R G; Andrews, P A (1997) The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol 39:217-22
Dennis, G C; Dehkordi, O; Millis, R M et al. (1996) Monitoring of median nerve somatosensory evoked potentials during cervical spinal cord decompression. J Clin Neurophysiol 13:51-9
Canada, R G; Andrews, P A; Mack, K M et al. (1995) The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta 1267:25-30
Ting, P; Xu, S; Krumins, S (1994) Endogenous opioid system activity following temporary focal cerebral ischemia. Acta Neurochir Suppl (Wien) 60:253-6
Canada, R G (1993) Calcium receptor binding of cisplatin and terbium in human breast tumor cells after hyperthermia. Radiat Res 133:170-5